SCHIZOPHRENIA

Understanding Its Pathophysiology, Therapeutic Approaches, and Advances in Pharmacological Management

A narrative review article

Author: Dhiraj Sanjay Patil
Affiliation: P.S.G.V.P. Mandal's College of Pharmacy, Shahada, Maharashtra, India.
Corresponding author: Prof. Hitendra S. Chaudhary & Prof. Roshan M. Chaudhari.

Prepared as an original, publication-oriented synthesis of the supplied review report and selected authoritative clinical guidance.

Abstract

Schizophrenia is a complex and often long-term mental health condition that can affect perception, thinking, emotional expression, motivation and everyday functioning. It is not explained by a single cause or one isolated brain abnormality. Current understanding points towards an interaction among genetic susceptibility, early neurodevelopment, environmental exposures and changes in the communication systems that connect different brain regions. Symptoms are commonly discussed in three broad domains: positive symptoms, such as hallucinations and delusions; negative symptoms, such as reduced motivation and social withdrawal; and cognitive difficulties involving attention, memory and executive functioning.

Antipsychotic medicines remain central to the management of acute psychotic symptoms and relapse prevention. However, medication alone is rarely sufficient to address every aspect of the condition. Psychological interventions, family education, social-skills development, rehabilitation, supported education or employment, and attention to physical health contribute to a more complete model of care. Treatment must be individualised because antipsychotic medicines differ in their effectiveness and adverse-effect profiles. Important safety concerns include metabolic changes, movement disorders, sedation, raised prolactin, cardiovascular effects and, rarely, neuroleptic malignant syndrome. Tardive dyskinesia is a particularly important long-term movement disorder that requires recognition and clinical review.

This narrative review brings together the key themes of the supplied academic report: aetiology, neurobiology, clinical presentation, diagnosis, pharmacological and psychosocial treatment, medicine-related risks, and the role of pharmacists. It also places these themes in the context of contemporary guidance, with emphasis on shared decision-making, early assessment, systematic monitoring and recovery-oriented care. The central message is that schizophrenia is treatable and that sustained, respectful, person-centred support can improve symptoms, functioning and quality of life.

Keywords: Schizophrenia; psychosis; pathophysiology; dopamine; antipsychotic medicines; psychosocial intervention; adverse drug reactions; medication adherence; pharmacist; recovery.

1. Introduction

Schizophrenia is a serious mental health condition in which a person may experience changes in the way reality is perceived, interpret information differently, or find it difficult to organise thoughts and behaviour. The condition can influence education, employment, relationships, independent living and physical health. Its effects vary considerably: some people experience periods of acute symptoms followed by improvement, while others have persistent difficulties that require longer-term support. A diagnosis should never be used to define a person or to overlook their strengths, goals and capacity for recovery.

The World Health Organization estimates that around 27 million people worldwide live with schizophrenia, approximately one person in every 300. The condition is associated with substantial disability and a shorter average life expectancy, partly because physical illnesses and barriers to healthcare may go unrecognised or undertreated [1]. At the same time, effective care is available. The WHO notes that at least one in three people with schizophrenia may achieve full recovery, while many others can make meaningful progress with appropriate treatment and support [1].

Historically, schizophrenia was often described mainly in terms of hallucinations and delusions. Clinical understanding is now broader. Cognitive impairment, reduced motivation, social withdrawal, physical comorbidity, stigma, housing insecurity and difficulty obtaining or retaining work are also important. Therefore, treatment goals should extend beyond reducing acute symptoms. They should include helping the person

maintain relationships, participate in education or employment, manage physical health and make decisions about their own care.

This article is based primarily on the supplied practice-school report on therapeutic approaches and pharmacological management of schizophrenia. The original report discusses genetic and environmental contributions, dopamine and acetylcholine, neurodevelopment, clinical manifestations, diagnosis, treatment, adverse effects and pharmacists' responsibilities. Selected statements have been clarified using current authoritative guidance where the report contains outdated terminology or claims that require qualification.

2. Aetiology and Risk Factors

The precise cause of schizophrenia is not known. The most accepted explanation is a multifactorial model in which inherited vulnerability interacts with biological development and environmental experiences. No single gene, life event or biochemical change is sufficient to explain every case. This is important when discussing risk with families: having a relative with schizophrenia may increase risk, but it does not mean that another family member will inevitably develop the condition.

2.1 Genetic contribution

Family, twin and genomic studies indicate that genetic factors contribute substantially to susceptibility. Genome-wide association studies examine common variations across the DNA of large groups of people to identify genetic regions associated with a condition. These studies have identified many risk-associated variants, each generally making a small contribution. Other research has examined copy-number variants, in which sections of DNA are deleted or duplicated. Certain rare variants can have a stronger effect, but they account for only a minority of cases.

Genetic findings do not provide a simple predictive test for an individual. Risk is distributed across many genes and is influenced by non-genetic factors. For this reason, genetic information is most useful for understanding the biology of schizophrenia and identifying pathways for research rather than assigning a definite outcome to a person.

2.2 Environmental and developmental influences

The supplied report describes several environmental and developmental factors that have been investigated, including prenatal complications, maternal stress, infection, nutritional difficulties, childhood adversity, bullying, social exclusion, discrimination, unemployment and housing insecurity. These associations should be interpreted carefully. A risk factor is not necessarily a direct cause, and an association observed in a population does not establish that the same factor caused illness in a particular person.

The neurodevelopmental hypothesis proposes that differences in brain development may begin before birth or during early life and become more apparent as the brain matures. A commonly discussed model suggests that early vulnerability may interact with later developmental events, including changes in brain connectivity during adolescence. Subtle difficulties in cognition, social interaction or behaviour may sometimes appear before a first clear psychotic episode, but such experiences are not specific to schizophrenia and should not be treated as a diagnosis.

Social and economic conditions also matter. Trauma, isolation, discrimination and unstable housing can increase distress and make it harder to access consistent care. These influences are relevant not only to risk but also to recovery. Safe housing, supportive relationships, meaningful activity and accessible health services can help people remain engaged in treatment and rebuild daily routines.

3. Pathophysiology and Neurobiology

Schizophrenia is associated with changes in brain networks involved in perception, motivation, memory, attention and the interpretation of social information. Research has identified structural and functional differences in some people, including changes in grey matter, white-matter connections and activity within particular neural circuits. These findings are variable and are not currently sufficient to diagnose schizophrenia in an individual. Diagnosis remains clinical, based on a careful assessment of symptoms, duration, functioning and alternative explanations.

3.1 Dopamine pathways

Dopamine is a neurotransmitter involved in motivation, reward learning, movement and the assignment of importance to experiences. The dopamine hypothesis has been influential because many antipsychotic medicines reduce dopamine D2-receptor signalling, and this action is related to their ability to improve psychotic symptoms. Evidence suggests that increased presynaptic dopamine activity in parts of the striatum is relevant to psychosis in at least some individuals.

The dopamine model is useful but incomplete. It does not explain every symptom, every patient or all aspects of cognitive and negative symptoms. It is therefore more accurate to view dopamine dysfunction as one part of a wider network disturbance rather than as the sole cause of schizophrenia.

3.2 Acetylcholine and other neurotransmitter systems

Acetylcholine contributes to attention, learning and memory. Cholinergic signalling occurs through muscarinic and nicotinic receptors, and research has explored how these systems may relate to cognitive symptoms in schizophrenia. Medicines with anticholinergic effects can sometimes worsen memory, attention, constipation, dry mouth or blurred vision. Clinicians therefore need to review the total anticholinergic burden, especially when several medicines are prescribed.

Glutamate, GABA and other signalling systems are also under investigation. Glutamate is a major excitatory neurotransmitter, while GABA is a major inhibitory neurotransmitter. Healthy brain function depends on a balance between excitation and inhibition. Disturbances in this balance may affect how information is processed across neural circuits and may contribute to cognitive and perceptual difficulties. These mechanisms remain active areas of research.

3.3 Neuroinflammation, oxidative stress and biomarkers

The supplied report discusses neuroinflammation, immune-system changes and oxidative stress as possible contributors to the biology of schizophrenia. These areas are scientifically important, but they should not be presented as established single causes or routine diagnostic tests. Researchers are investigating whether combinations of blood markers, imaging measures, electrophysiological findings and genetic data may eventually help identify subgroups or predict treatment response.

Electroencephalography (EEG) records electrical activity from the scalp. The report refers to EEG microstate analysis and machine-learning approaches that have been studied for distinguishing groups of people with schizophrenia from healthy comparison groups. Such results are promising as research findings, but a high classification accuracy in a particular dataset does not establish a clinically validated diagnostic test. Larger, independent studies and real-world validation are needed before these methods can guide routine diagnosis.

4. Clinical Manifestations

Symptoms differ between individuals and may change over time. They are commonly grouped into positive, negative and cognitive domains. The term "positive" does not mean beneficial; it refers to experiences that are added to ordinary perception or thought. "Negative" symptoms refer to reductions in usual emotional expression, motivation or social engagement.

4.1 Positive symptoms

Hallucinations are sensory experiences that occur without an external stimulus. Auditory hallucinations, such as hearing voices, are frequently reported, although visual, tactile, olfactory and other experiences may also occur. A person experiencing a hallucination may find it vivid and convincing. Responding calmly, listening without ridicule and arranging professional assessment are more helpful than arguing or dismissing the experience.

Delusions are strongly held beliefs that remain fixed despite clear evidence to the contrary. Examples may include beliefs that one is being watched, followed, harmed or controlled. Disorganised thinking may be reflected in speech that is difficult to follow, shifts between unrelated topics or lacks a clear sequence. Behaviour can also become disorganised, and some people experience marked agitation or unusual motor behaviour.

4.2 Negative symptoms

Negative symptoms may include reduced emotional expression, limited speech, low motivation, reduced ability to experience pleasure, difficulty initiating activities and withdrawal from social contact. These symptoms can be especially disabling because they may interfere with self-care, education, work and relationships even when hallucinations or delusions have improved. Negative symptoms should be assessed carefully because depression, medication adverse effects, substance use and physical illness can produce similar features.

4.3 Cognitive symptoms

Cognitive difficulties may affect attention, working memory, learning, processing speed, planning and problem-solving. A person may understand information but need more time to organise a response, remember instructions or manage several tasks at once. These difficulties can influence educational and occupational performance. Clear communication, written reminders, predictable routines and practical rehabilitation may help reduce their impact.

5. Diagnosis and Assessment

There is no single blood test, brain scan or EEG finding that can independently confirm schizophrenia. Diagnosis is made by a qualified mental health professional through a comprehensive clinical assessment. The assessment considers the nature of symptoms, how long they have been present, their effect on functioning, the person's medical and psychiatric history, substance use, prescribed medicines and possible alternative explanations.

A careful differential diagnosis is essential because psychotic symptoms can occur in several conditions. These include mood disorders with psychotic features, bipolar disorder, severe depression, substance- or medication-induced psychosis, neurological disorders and some medical illnesses. Symptoms may overlap, so the clinician evaluates their timing, relationship to mood changes, course and associated features. Physical examination and appropriate investigations may be needed to identify other causes.

The report lists traditional categories such as paranoid, disorganised (hebephrenic), catatonic, undifferentiated and residual schizophrenia. These labels are historically important, but they are no longer used as formal schizophrenia subtypes in DSM-5 because they were not sufficiently stable or reliable over time [2]. Contemporary assessment focuses more on the pattern and severity of symptoms, course of illness, functioning

and individual needs. Catatonia may still be assessed as a clinically important syndrome, but it is not a current schizophrenia subtype.

Assessment should be broad rather than limited to psychotic symptoms. NICE guidance recommends considering psychiatric history, physical health, substance use, developmental history, trauma, social relationships, accommodation, education, employment and quality of life [3]. Early specialist assessment is important when a person presents with a first episode of sustained psychosis.

6. Pharmacological Management

Antipsychotic medicines are a central component of treatment for many people with schizophrenia. They can reduce hallucinations, delusions and disorganised thinking and can lower the risk of relapse when used as part of an agreed treatment plan. The choice of medicine is individual. It depends on previous response, symptom profile, physical health, other medicines, likely adverse effects, personal preference and practical considerations.

6.1 First-generation antipsychotics

First-generation, or typical, antipsychotics include medicines such as haloperidol and chlorpromazine. Many act mainly by blocking dopamine D2 receptors. They can be effective for positive symptoms, but the likelihood of extrapyramidal adverse effects varies by medicine and dose. These effects may include acute dystonia, akathisia, drug-induced parkinsonism and tardive dyskinesia. Some medicines in this group can also cause sedation, postural hypotension and anticholinergic effects.

6.2 Second-generation antipsychotics

Second-generation, or atypical, antipsychotics include medicines such as risperidone, olanzapine, quetiapine, amisulpride, aripiprazole and clozapine. Their receptor actions differ, and their adverse-effect profiles are not interchangeable. Some have a greater tendency to cause weight gain, changes in blood glucose or lipid levels; others may be more likely to raise prolactin or cause movement-related effects. It is therefore misleading to assume that every second-generation medicine is free of movement disorders or that all medicines in the group have the same metabolic risk.

Clozapine has a specific role for people whose schizophrenia has not responded adequately to other antipsychotic trials. It can be highly beneficial in treatment-resistant illness, but it requires specialist supervision and regular blood monitoring because of potentially serious adverse effects, including severe neutropenia, myocarditis, seizures and metabolic complications. It should not be started, stopped or adjusted without the treating team’s direction.

6.3 Individualised prescribing and adherence

A good prescribing process is a shared decision. The clinician and patient should discuss expected benefits, possible adverse effects, personal priorities and the time needed to judge response. NICE recommends starting at the lower end of the licensed dose range and increasing gradually when appropriate, while recording the rationale for treatment decisions. An adequate therapeutic trial is generally assessed over several weeks, with ongoing review of symptoms and tolerability [3].

Some people may benefit from long-acting injectable formulations, particularly when they prefer this option or when missed doses have contributed to relapse. These formulations are not a punishment or a sign of failure; they are one possible way to make treatment more practical. The decision should be made collaboratively, taking account of the person’s preferences and the benefits and disadvantages of injections.

Medication should not be stopped abruptly without medical advice. Sudden discontinuation may lead to symptom recurrence or withdrawal-related difficulties. If an adverse effect is troublesome, the prescriber may

consider dose adjustment, a carefully planned switch or treatment of the adverse effect. Any change should be supervised and monitored.

7. Psychosocial and Supportive Treatment

Recovery involves more than controlling symptoms. Psychosocial interventions help people build coping strategies, strengthen relationships, improve daily functioning and work towards personal goals. They should be integrated with medication when clinically appropriate rather than treated as optional extras.

7.1 Psychoeducation and family intervention

Psychoeducation provides understandable information about the condition, treatment choices, early warning signs of relapse and ways to seek help. Family interventions can help relatives understand symptoms, communicate more effectively and reduce avoidable conflict or stress. With the person's consent, family members can become valuable partners in supporting treatment and identifying changes that may need clinical attention.

7.2 Cognitive behavioural therapy and social skills

Cognitive behavioural therapy for psychosis can help a person examine distressing experiences, develop alternative coping strategies and reduce the impact of symptoms. It does not require the therapist to argue with the person about their beliefs. Social-skills training can support communication, problem-solving and confidence in everyday interactions. These approaches may be particularly useful when social withdrawal or difficulties interpreting social cues interfere with relationships.

7.3 Rehabilitation, housing and employment

Psychosocial rehabilitation may include life-skills training, supported education, vocational rehabilitation, supported employment and assistance with independent living. Stable housing can reduce stress and make it easier to attend appointments, maintain routines and take medication consistently. Meaningful work or study can improve confidence and social participation when the environment is supportive and expectations are realistic.

Electroconvulsive therapy (ECT) is not a routine treatment for schizophrenia. It may be considered by specialists in selected circumstances, such as particular severe or treatment-resistant presentations or when catatonia is present, after an individual assessment. It should be described as a specialised option rather than a standard intervention for every patient.

8. Adverse Effects and Safety Monitoring

Antipsychotic medicines can be effective, but their potential adverse effects must be discussed and monitored. The aim is to find a treatment that provides meaningful benefit with the lowest reasonable burden of side effects. A person should be encouraged to report new symptoms rather than silently stopping treatment.

8.1 Metabolic and cardiovascular effects

Some antipsychotics can contribute to weight gain, increased appetite, dyslipidaemia and changes in blood glucose. These effects may increase long-term cardiovascular and diabetes risk. Monitoring commonly includes weight, waist circumference, blood pressure, glucose or HbA1c, and lipid profile. NICE recommends baseline assessment before treatment and systematic follow-up during treatment [3]. An ECG may be appropriate when indicated by the medicine's product information, cardiovascular history, examination findings or inpatient status.

8.2 Extrapyramidal symptoms and tardive dyskinesia

Extrapyramidal symptoms are movement-related adverse effects. Acute dystonia may involve sudden muscle contractions; akathisia is experienced as inner restlessness and an urge to move; and drug-induced parkinsonism can include stiffness, tremor and slowed movement. These symptoms can be distressing and may be mistaken for anxiety or worsening psychiatric illness, so direct assessment is important.

Tardive dyskinesia is a potentially persistent movement disorder associated with prolonged exposure to dopamine-receptor-blocking medicines. It may involve involuntary movements of the tongue, lips, jaw, face, trunk or limbs. Early recognition is important. The treating clinician may review the diagnosis, medicine, dose and risks of changing treatment. Specialist options, including vesicular monoamine transporter 2 (VMAT2) inhibitors in appropriate settings, may be considered according to local approvals and clinical guidance [4]. Patients should not independently reduce or discontinue antipsychotic medication.

8.3 Sedation, prolactin and anticholinergic effects

Sedation can interfere with driving, study, work and social activity. Raised prolactin may contribute to menstrual changes, sexual dysfunction, breast symptoms or reduced bone health over time. Anticholinergic effects may include dry mouth, constipation, blurred vision, urinary difficulties and cognitive slowing. The clinical response depends on severity and the medicine involved; options may include dose review, switching medicines or targeted management.

8.4 Orthostatic hypotension and neuroleptic malignant syndrome

Orthostatic hypotension is a fall in blood pressure after standing. It can cause dizziness, fainting and falls, particularly during treatment initiation or dose changes. Patients may be advised to rise slowly and report repeated dizziness. Dehydration, other medicines and underlying medical conditions can increase risk.

Neuroleptic malignant syndrome is rare but potentially life-threatening. Warning features can include high fever, severe muscle rigidity, altered mental state and autonomic instability such as unstable pulse or blood pressure. Suspected neuroleptic malignant syndrome requires urgent emergency medical assessment. It should never be managed by simply waiting for symptoms to settle.

9. Role of the Pharmacist

Pharmacists are accessible healthcare professionals who can support safe and effective medicine use. Their role extends beyond dispensing. In collaboration with psychiatrists, physicians, nurses and other members of the care team, pharmacists can review prescriptions, identify interactions, explain treatment and help patients manage adverse effects.

Medication counselling should use clear, non-judgemental language. Patients may need information about why a medicine has been prescribed, how and when to take it, what to do after a missed dose, how long treatment may take to show benefit and which adverse effects require prompt attention. Counselling should invite questions and recognise that concerns about weight gain, sedation, sexual effects or movement symptoms can strongly influence willingness to continue treatment.

Medication review is another important responsibility. Pharmacists can check for duplicate therapy, unnecessary anticholinergic medicines, interactions with prescribed or non-prescribed products and potential problems associated with multiple medicines. They can help monitor adherence without blaming the patient and explore practical barriers such as cost, forgetfulness, complex schedules, stigma or limited family support.

Pharmacists can also reinforce the importance of routine follow-up and physical-health monitoring. They should encourage patients to attend recommended checks for weight, blood pressure, glucose, lipids and movement

symptoms. When a patient reports a serious or unexpected adverse effect, the pharmacist should refer promptly to the prescriber or emergency service as appropriate. Pharmacists do not replace psychiatric assessment or independently alter specialist treatment; their contribution is strongest when integrated into a coordinated care plan.

10. Challenges and Future Perspectives

Despite advances in treatment, several challenges remain. Some people do not receive timely specialist care, while others face stigma, discrimination, financial hardship or fragmented services. Negative and cognitive symptoms may persist even after positive symptoms improve. Physical health problems can be missed, and medicine adverse effects may reduce adherence. These issues show why long-term care needs to address the whole person rather than focusing only on symptom scores.

Research is exploring genetic and epigenetic mechanisms, neuroinflammation, oxidative stress, glutamate and GABA signalling, brain connectivity, EEG patterns and machine-learning methods. These approaches may eventually help identify biologically meaningful subgroups or predict which treatment is most likely to help a particular person. However, promising research findings should not be confused with validated clinical tools. Any proposed biomarker must be tested in diverse populations and shown to improve decisions and patient outcomes.

The report's discussion of EEG microstates and machine learning is an example of this emerging field. A reported high classification accuracy can be encouraging, but accuracy alone does not establish clinical usefulness. Researchers must also evaluate sensitivity, specificity, reproducibility, external validation, bias, cost and whether the tool adds value beyond a careful clinical assessment.

Future progress will also depend on service design. Community-based mental health care, early-intervention pathways, accessible psychological therapies, supported housing, employment programmes and family education can make treatment more practical and humane. Recovery-oriented services should respect autonomy, involve people in decisions and recognise that recovery may mean different things to different individuals.

11. Conclusion

Schizophrenia is a complex condition shaped by interacting genetic, neurodevelopmental, neurobiological and environmental influences. Its presentation may include positive symptoms, negative symptoms and cognitive difficulties, with substantial variation between individuals. Diagnosis requires a careful clinical assessment and consideration of alternative medical, psychiatric and substance-related explanations. Traditional schizophrenia subtypes are no longer used in DSM-5, and current practice places greater emphasis on the person's symptom pattern, course and functional needs.

Antipsychotic medicines remain an important part of treatment, but their benefits must be balanced against possible adverse effects through individualised prescribing and regular monitoring. Psychosocial interventions, family support, rehabilitation, stable housing and opportunities for education or employment are also essential components of care. Pharmacists contribute by promoting safe medicine use, supporting adherence, identifying adverse effects and helping patients remain connected with their healthcare team.

The most important message is that schizophrenia is not a personal failure and should not be a reason for exclusion. With early assessment, appropriate treatment, respectful communication and sustained community support, many people can achieve meaningful improvement and pursue fulfilling lives. Future research may refine diagnosis and treatment, but person-centred care remains central today.

12. References

[1] World Health Organization. Schizophrenia. Fact sheet. 11 September 2026. Available at: https://www.who.int/en/news-room/fact-sheets/detail/schizophrenia (accessed 17 November 2026).

[2] American Psychiatric Association. DSM-5: Changes in the diagnosis of schizophrenia. Available at: https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/DSM/APA_DSM-5-Schizophrenia.pdf (accessed 17 November 2026).

[3] National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. Updated 4 September 2026. Available at: https://www.nice.org.uk/guidance/cg178 (accessed 17 November 2026).

[4] Japanese Society of Neuropsychopharmacology and Japanese Society of Clinical Neuropsychopharmacology. Guideline for pharmacological treatment of schizophrenia 2022. Neuropsychopharmacology Reports. 2025;45:e12497. See also: https://pmc.ncbi.nlm.nih.gov/articles/PMC11666347/.

[5] McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19:15–33. doi:10.1002/wps.20693.

[6] Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry. 2005;10:40–68. doi:10.1038/sj.mp.4001558.

[7] Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Archives of General Psychiatry. 2003;60:1187–1192.

[8] Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. American Journal of Psychiatry. 2020;177:868–872.

[9] Barnes TRE, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology. 2020;34:3–78.

[10] Galletly C, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian & New Zealand Journal of Psychiatry. 2016;50:410–472.

[11] Kahn RS. On the origins of schizophrenia. American Journal of Psychiatry. 2020;177:291–297.

[12] Dennison CA, Legge SE, Pardiñas AF, Walters JTR. Genome-wide association studies in schizophrenia: recent advances, challenges and future perspective. Schizophrenia Research. 2020;217:4–12.

[13] Martini LC, Barbosa Neto JB, Petreche B, et al. Schizophrenia and work: aspects related to job acquisition in a follow-up study. Revista Brasileira de Psiquiatria. 2018;40:35–40.

Publication and originality note

This manuscript is an original paraphrased synthesis prepared from the supplied practice-school report and the additional sources listed above. It is not a verbatim reproduction of the report. Scientific ideas, clinical recommendations and factual claims are not made copyright-free by paraphrasing; sources must still be acknowledged, and the target website or journal may require a specific citation style, word count, author declaration or plagiarism screening. No one can guarantee that a manuscript will receive no similarity match or that it is automatically cleared for publication. Before submission, the author should verify every reference, confirm author and affiliation details, check the target publisher’s requirements, and obtain qualified clinical review of medical content. This article is educational and is not individual medical advice.